Eloralintide

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

176 competitors in Obesity

#DrugCompanyPhaseTrials

1

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 3

12

Maridebart Cafraglutide

Amgen

Phase 3

113

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

14

Cagrisema

Novo Nordisk

Phase 3

55

Belantamab Mafodotin-Blmf

Novo Nordisk

Phase 3

16

Eloralintide

Eli Lilly

Phase 3

137

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Phase 3

18

Actemra

Roche

Preclinical

29

Avapro

Sanofi

Preclinical

110

Amidate

Pfizer

Preclinical

—Show 34 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity13 trials

A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Recruiting·Eli Lilly·Phase 3·NCT07881458·1,000 enrolled

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes

Recruiting·Eli Lilly·Phase 3·NCT07282600·1,035 enrolled

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

Recruiting·Eli Lilly·Phase 3·NCT07392190·900 enrolled

Show 10 more trials

A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes

Not yet recruiting·Eli Lilly·Phase 3·NCT07881432·2,115 enrolled

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk

Not yet recruiting·Eli Lilly·Phase 3·NCT07900633·3,000 enrolled

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

Active, not recruiting·Eli Lilly·Phase 2·NCT07215559·200 enrolled

A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Recruiting·Eli Lilly·Phase 2·NCT07589608·400 enrolled

A Phase 1, Open-Label Study to Evaluate the Effect of Eloralintide on the Pharmacokinetics of the Combined Oral Contraceptive Levonorgestrel-Ethinyl Estradiol in Female Participants With Obesity or Overweight

Recruiting·Eli Lilly·Phase 1·NCT07808060·34 enrolled

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes

Recruiting·Eli Lilly·Phase 3·NCT07321886·1,980 enrolled

A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight

Recruiting·Eli Lilly·Phase 1·NCT07738614·56 enrolled

A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macupatide Monotherapy, and Macupatide in Combination With Eloralintide, in Japanese Participants With Obesity or Overweight Without Type 2 Diabetes.

Not yet recruiting·Eli Lilly·Phase 1·NCT07765511·60 enrolled

A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Eloralintide on Insulin Sensitivity and Metabolism in Adult Participants With Overweight or Obesity

Recruiting·Eli Lilly·Phase 1·NCT07665879·115 enrolled

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Completed·Eli Lilly·Phase 2·NCT06230523·263 enrolled

Overweight2 trials

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

Completed·Eli Lilly·Phase 1·NCT06916091·30 enrolled

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Completed·Eli Lilly·Phase 1·NCT06916065·188 enrolled

Osteoarthritis1 trial

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)

Recruiting·Eli Lilly·Phase 3·NCT07353931·900 enrolled

Sleep Apnea, Obstructive1 trial

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight

Recruiting·Eli Lilly·Phase 3·NCT07369011·800 enrolled

Unspecified1 trial

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Two Eloralintide Solutions in Healthy Participants

Active, not recruiting·Eli Lilly·Phase 1·NCT07701083·58 enrolled

Details

Drug Info

Related News